Connect with us

CBD

Rare Cannabinoids Are the Next Frontier in the Marijuana Industry

Published

on

A worker in a cannabis greenhouse. Uriel Sinai / Getty Images

It’s 2021 and regular THC won’t cut it for the burgeoning cannabis industry. Neither does CBD. Instead, many startups are betting that cannabis users are craving for something that nature alone cannot provide.

In Berkeley, California, startup Demetrix is ​​preparing to manufacture “metric tons” of cannabigerol, also known as CBG. CBG is also called “the mother of cannabinoids” because it is a chemical precursor to hundreds of other chemicals found in trace amounts in cannabis plants.

“It’s been a wild ride,” said Cynthia Bryant, Demetrix’s chief business officer observer. “Three years ago we literally had empty laboratory space. We bought freezers. ”Now they hope to have CBG products ready to use by the end of the year.

Cannabis users are increasingly interested in niche or “rare” cannabinoids, although it is still unclear what these molecules are really capable of. This includes products like Delta 8 THC, which is about half as strong as regular THC and than that. referred to as fastest growing segment the hemp industry. Companies like Demetrix are more interested in “rare” cannabinoids – over 100 compounds in cannabis that only occur in traces in nature but can be produced in abundance in the laboratory.

Demetrix scientists in their laboratory. Demetrix

Demetrix was originally founded by Jay Keasling, a professor at the University of California, Berkeley who focuses on developing microbes, especially yeast, to manufacture other substances: like fuel or an ingredient in anti-malarial drugs called artemisinin. Keasling has since turned to cannabis, where his patented technique gives brewer’s yeast the ability to make cannabinoids.

“It’s like brewing beer,” says Keasling Observer. “We feed the yeast, the sugar and the yeast, instead of spitting out ethanol, spitting out cannabinoids.”

Demetrix is ​​just one of a handful of startups poised to embark on a new path in the cannabis industry that is similar to the path taken by CBD, or more recently, Delta-8 THC. Dennis O’Neill, the president of Biomedican, another California-based startup, estimates that the rare cannabinoid industry could be worth it $ 25 billion by 2025.

Biomedican also uses proprietary yeasts to mass-produce rare cannabinoids like CBG and has amassed $ 4.1 million in funding to date.

“There’s a percentage of CBD people who are looking for the next best thing,” says O’Neill Observer. “All of the data points indicate that we have a demand tsunami that will hit this market. There will be a lot of money to be made. ”

Where do the rare cannabinoids come from?

It’s not that we didn’t know these molecules existed in cannabis, but that they were historically inaccessible. Molecules like CBG are usually only present in traces in natural plants – although some varieties can be bred contain more of a certain rare cannabinoid.

The biosynthetic approach excludes the plant from the equation and focuses on the molecular machinery of cannabis to boost the production of rare cannabinoids.

The end result is an isolated form of a rare cannabinoid. It’s the same product that would naturally exist, but without the extra terpenes or other molecules present in a plant (a disadvantage some weed connoisseurs might say, but one that emerging industries see as an advantage) .

The idea that scientists succeeded in developing yeast to produce rare cannabinoids, thereby circumventing the scarcity of nature, has existed for several years. Keasling first published a piece of paper on the subject in 2019, but at that point it was not clear whether the process could be scaled up enough to support a new industry.

Bryant says that faster data processing, advances in microorganism engineering and a better understanding of cannabis helped Demetrix go from zero liters of CBG to 15,000 liters in three years. In February, Demetrix also signed an agreement with a commercial manufacturer promising to supply these “metric tons” of CBG.

Fermentation tanks on a laboratory scale. Demetrix

Biomedican also expanded its operations this year, says O’Neill. Covid-19 has delayed the arrival of the equipment, but it expects it will be operational by the end of the year. “Our plan is to produce here in the US and then build a plant in Mexico, Europe and then Asia,” he says.

However, if everything stays on track, he expects to be in high-volume production of rare cannabinoid products – mostly CBG – by 2023 (they have already moved into pilot production). Biomedican already plans to distribute its products in Mexico.

That could range from cosmetics and lotions to granola bars, chocolates, or pet grooming products – the same products that became breeding grounds for CBD. This also means that it is possible that rare cannabinoids, once they are as freely available as CBD, fall into the same traps as CBD.

CBD has medicinal benefits. It forms the basis of the FDA-approved epilepsy drug Epidiolex and is used to treat pain. But it has also built a reputation for treating conditions ranging from anxiety to erectile dysfunction. according to an analysis of the posts on the r / CBD subreddit.

As the introduction of CBD demonstrated, the novelty of certain cannabinoid products can create both an exciting and chaotic experience for people watching new products arrive on store shelves. CBD products are not reviewed by the FDA before they go on sale, nor are companies may say CBD products can treat any diagnosable condition. However, you can make “general wellness” claims.

“There is so much going on for the individual consumer,” says Paul Seaborne, professor of commerce at the University of Virginia. “They don’t necessarily have the same support and guidance from their GP or from normal sources.”

Keasling admits that the CBD industry has some element of the “snake oil” sales art. The rare cannabinoid industry could very well go that route. Rare cannabinoids have their share of the hype, and as manufacturing increases, they will hit consumers in successive waves, with science lagging behind as to what they can actually achieve.

“I would like these companies that work with technical microbes to deal with them a little better,” says Keasling.

Research to date on rare cannabinoids is currently sparse. This is mainly because it was nearly impossible to isolate these compounds in large quantities and because marijuana’s status as a List I drug has made such studies difficult to conduct. Seaborne estimates that thanks to this planning, the pace of cannabis research has stalled by 30-50 years.

So far, research into rare cannabinoids has contained some nuggets of information that allude to certain health effects. Previous studies on CBG suggest that it may show promise as a treatment Glioblastoma, psoriasis, or Neurodegenerative Diseases to like AS (these studies were carried out on mice and cells). Another one is running clinical study on the effects of cannabigerol on human diseases, which is registered with Clinicaltrials.gov at the time of writing.

Rodent studies on THCV, another rare cannabinoid, have suggested that it can decrease appetite and upregulate metabolism (again, no ongoing clinical trials are registered on this at this time). There are three clinical trials of THCV on Clinicaltrials.gov – one has published results and suggests it could help people with type II diabetes control blood sugar levels.

But these rodent studies are enough for O’Neill to predict that THCV will be the next rare cannabinoid to boom.

Incidentally, Demetrix and Biomedican are betting that these rare molecules have previously undiscovered effects. Even Keasling suggests that we might discover that some rare cannabinoids are “worthless” once the research is done, but not much of that research has happened yet.

Both companies also plan to support them by making rare cannabinoids available for clinical trials.

“We do our own basic research to understand these cannabinoids, but we also look for others to help us figure out what each of these cannabinoids can be of benefit to consumers,” says Bryant. “This is a class of compounds that modern scientific evaluation has completely skipped.

“I don’t think there are many connections we can say that about.”

In the meantime, companies plan to venture into even darker areas of cannabinoid manufacturing – ones that don’t even exist in natural plants.

Keasling’s original work suggests that his method could be used to cultivate “unnatural cannabinoids”. Biomedican announced the synthesis of a type of cannabinoid called Sesqui-CBG, a chemical variation of regular CBG.

A biomedical scientist Press release suggests that sesqui cannabinoids contain properties of many other cannabinoids combined, but Biomedican CEO Maxim Mikheev warns that we don’t know much about them.

“Sesqui cannabinoids haven’t been studied very well,” he says Observer.

Fear of the unknown doesn’t seem to be a problem that affects most cannabis users. Despite ongoing research into what cannabinoids can and can’t do, these molecules still have the enticing appeal of untapped potential. After 50 years of hesitant research, nobody knows exactly what we might find.

“Despite all this confusion, despite the fast pace of things, consumers are giving” [cannabis products] give it a try, ”says Seaborne. “This is proof of how much desire there is.”

Cannabinoids are the next big thing in the pot industry, but who can mass-produce them?

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

CBD

Medical Cannabis Market Size to Reach 47.15 Billion in 2027

Published

on

VANCOUVER, BC, July 26, 2021 / PRNewswire / – The medical cannabis market is expected to reach global size $ 47.15 billion in 2027 at a CAGR of 16.9%, according to the latest report from Emergen Research. The growth in market revenue can be attributed to the increasing use of medical cannabis to treat diseases and conditions, increasing research and development activities, and the legalization of cannabis in various countries around the world. Increasing government initiatives to promote the safe use and consumption of the product are also a key factor that is expected to contribute to the market growth over the forecast period.

Medical cannabis is cannabis and cannabinoids that are prescribed by doctors and health professionals to relieve symptoms or treat illness. Preliminary studies suggest that cannabis may reduce nausea and vomiting, which are primary side effects of chemotherapy, improve appetite in people with HIV / AIDS, and relieve chronic pain and muscle spasms. Medicinal cannabis can be administered through capsules, tinctures, skin patches, and cannabis edibles, among other things. The increasing incidence of serious and chronic diseases such as cancer, Parkinson’s, Alzheimer’s and ALS, among other things, has encouraged the use of medicinal cannabis and led to the development of new products. In addition, cannabinoids are increasingly recommended for the treatment of anorexia, arthritis, migraines, and glaucoma when other treatment regimens are ineffective. This is expected to further spur the market’s revenue growth over the forecast period.

Click here to access a free sample PDF copy of the of [email protected] https://www.emergenresearch.com/request-sample/174

Increasing research and development to study the medical uses of cannabis and the availability of synthetic cannabinoids as prescription drugs are some other key factors that are expected to contribute to future sales growth of the market. However, the lack of data on the long-term safety of medical cannabis, chronic side effects such as fatigue, dizziness and hallucinations, and the implementation of strict regulatory guidelines for the cultivation and marketing of cannabis are some key factors that are expected to continue to slow market growth .

Some key highlights in the report:

  • Oil segment sales are expected to grow at a CAGR of 17.5% over the forecast period due to increasing demand for hemp oil for clinical purposes such as reducing depression and anxiety, and relieving cancer symptoms and related pain.
  • The chronic pain segment is expected to account for the largest share of sales over the forecast period, as medicinal cannabis is primarily used to treat chronic pain and involuntary muscle spasms. Cannabis is used to treat chronic pain associated with many diseases and conditions, including multiple sclerosis, nerve pain, Parkinson’s, and PTSD, among others.
  • The inhalation segment dominated other routes of administration in terms of sales share in the global market in 2019, due to the fact that inhalation is the most common route of administration. Advances in product development have led to the introduction of various types of inhalers to make it easier for patients to consume medicinal cannabis.
  • North America is expected to account for the largest share of sales in the world market between 2020 and 2027, as recreational and medicinal cannabis is legalized, the number of product launches increases, investments to accelerate research and development for medical cannabis increase, and the strong presence of key players and Manufacturers in the region.
  • Major companies in the market include Canopy Growth Corporation, Aphria, Inc., Aurora Cannabis, Maricann Group, Inc., Tilray, Cronos Group, Organigram Holdings, Inc., Vivo Cannabis, Tikun Olam, and Insys Therapeutics, Inc.
  • In July 2021, the Medical Cannabis Commission has 6 companies in. Medical marijuana licenses granted Georgia, United Statesto grow marijuana under government supervision, convert it into CBD oil and sell the products to eligible patients in. market Georgia.
  • In July 2021, the first medical marijuana app of its kind, EcoCaNN, developed by the international pharmaceutical company MediCane, was launched in. brought on the market Israel which will enable medical cannabis patients to consult and communicate with doctors who specialize in the field. MediCane focuses on the research and development of cannabis-based drugs.

Make a Payment [Buy your Exclusive copy]@ https://www.emergenresearch.com/select-license/174

For the purposes of this report, Emergen Research has segmented the global medical cannabis market by product type, application and route of administration, distribution channel, and region:

Product Type Outlook (Revenue, $ Billion; 2017-2027)

Application Outlook (Revenue, $ Billion; 2017-2027)

  • Chronic pain
  • Mental disorders
  • anorexia
  • Seizures
  • Muscle cramp
  • cancer
  • Other

Administrative Outlook Route (Revenue, $ Billion; 2017-2027)

  • Orally
  • Intravenously
  • inhalation
  • Currently

Sales Channel Outlook (Revenue, $ Billion; 2017-2027)

Check out the report description and table of contents of the market [email protected] https://www.emergenresearch.com/industry-report/medical-cannabis-market

Regional Outlook (Revenue, Billion USD; 2017-2027)

  • North America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • BENELUX
    • the rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
  • middle East & Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of MEA

Discover more reports from Emergen Research:

Cannabis market by product type (flower, concentrates, other), by compound (tetrahydrocannabinol, cannabidiol (CBD), balanced THC and CBD), by application (medicine, leisure, pain therapy, neurological health management, other) and regional forecasts for 2027

Drug Infusion Systems Market By Control Systems (Open Loop System, Closed Loop System), By Infusion Type (Continuous Infusion, Intermittent Infusion, Patient-Controlled Infusion, Total Parenteral Nutrition), By Route Of Administration, By Application, By End Use, And By Region Forecast To 2028

Compound Management Market by Solution (products and outsourcing services), by sample type (chemical compounds, biosamples), by application (drug research, gene synthesis, biobanking, others), by end-use (biopharmaceutical company, pharmaceutical company, biobank, CRO), and by region forecast by 2028

Nanotechnology market size, share, trends, by type (nanomaterials, nanocomposites, nano devices, nano tools), by industry (food and agriculture, health care, information and technology, environment, energy, cosmetics), and by region, forecast to 2028

In Vitro Fertilization: Overcoming Insurmountable Barriers to Infertility

Joint Reconstruction Devices: Addressing the Need for Long-Term Relief from Orthopedic Disease

Liquid Biopsy: A Revolution in Medical Oncology

About Emergen Research

Emergen Research is a market research and advisory firm that provides syndicated research reports, bespoke research reports, and advisory services. Our solutions focus solely on their purpose of locating, deliberately analyzing and analyzing changes in consumer behavior in various demographics and industries, and helping customers make smarter business decisions. We offer market research studies that ensure relevant and fact-based research across multiple industries including Healthcare, Touch Points, Chemicals, Types, and Energy. We constantly update our research offerings to ensure that our customers are informed about the latest trends in the market. Emergen Research has a strong base of experienced analysts from various specialist areas. Our industry experience and the ability to develop a specific solution for all research problems offer our customers the opportunity to secure a lead over their respective competitors.

Contact us:

Eric Lee
Sales specialist for companies
Emergeny research | Internet: www.emergenresearch.com
Direct line: +1 (604) 757-9756
E-mail: [email protected]
Facebook | LinkedIn | Twitter | Blogs
Read full press [email protected] https://www.emergenresearch.com/press-release/global-medical-cannabis-market

SOURCE Emergence Research

Continue Reading

CBD

CBD Topicals Benefits and Uses, and Most Common Types Available

Published

on

We take a look at CBD topicals and discuss their benefits and uses. We also look at the most common types of topicals, including creams, lotions, balms, patches, and oils, and how to use them.

Advances in the medical and recreational cannabis market have resulted in the launch of a wide variety of products. The effects of CBD on humans have been studied and found to be very beneficial in some aspects. Due to the combination of market growth and positive effects, many new types of CBD products have been launched. Some of these are known as topical agents, which are products that you don’t have to ingest, but that you have to apply to the skin in some way to get the desired effect.

Why use CBD topicals?

Before we talk about why someone should use CBD topicals, let’s take a quick look at what they are. A CBD topical is essentially a product that can be applied to the skin. Like a cream or lotion fortified with cannabidiol. Whether it’s cannabis patches or some kind of lotion, topicals can be very helpful in some situations. These topical agents are widely used for their anti-inflammatory properties and other skin health benefits.

Much research has been done on the use of such products. It has been suggested that CBD has some anti-inflammatory properties. This allows CBD topicals to alleviate certain skin problems and joint pain to some extent. There are other ways these products can help as well, which is why they are so popular these days.

Types of CBD Topicals

As mentioned earlier, there are different types of themes in the market today. Before using any cannabis product, it is helpful to go through some dosage guidelines so that you know exactly how to use cannabis in various forms. Now let’s go over some common topics that you can get today:

CBD cream

Perhaps the most common type of topical on the market is a CBD cream. Many CBD skin creams use broad spectrum cannabidiol. This type of cannabidiol contains no or very small amounts of THC. Research has found that such a cream can provide relief for some conditions, such as:

– arthritis; as found in this study on rats in 2016.

– Peripheral neuropathy; as noted in this 2020 study.

– jaw pain; as found in this 2019 study.

Aside from its benefits, cannabidiol cream is one of the easiest products to use in this category. All you have to do is apply it directly to the affected area like a regular cream and it can provide quick relief. Sometimes such a product can also help users get some sleep.

Benefits and uses of CBD topicals and the most common types available

CBD patch

This is another type of product that is great for those who want to get the benefits of cannabidiol without smoking anything. Cannabis patches can be applied to the affected part of the body and the effect can be felt in 5-15 minutes. These patches are great for quick pain relief and also have the anti-inflammatory properties of cannabidiol.

This is a very good method of delivering cannabidiol to the body for beginners as there isn’t much to do. They’re not very expensive either. And their effects are easy to control, as you can easily take them off if you feel overwhelmed in any way.

CBD lotion

Just like creams, CBD lotion can be applied directly to the skin. There are many strains available for people who want the benefits of cannabidiol along with those of a healthy skin lotion at the same time. The lotions are great for making the skin healthier and restoring damaged skin.

Think of a cannabidiol fortified lotion as your regular, moisturizing lotion, but with added benefits like reducing inflammation, soothing the skin, fighting dryness, and reducing dark spots and wrinkles.

Benefits and uses of CBD topicals and the most common types available

CBD balm

Balms are another great option for people looking for pain relieving and anti-inflammatory effects. These can be used on any part of the body that you experience pain and suffering. Like creams, balms provide fairly quick relief and require nothing more than to rub them into the skin.

CBD oil and butter

There are many other forms of cannabidiol topicals, two of which are oil and butter. There are different types of oil and butter, but as for the topicals. Both products are used directly on the skin. For example, there are facial oils that can be dabbed around the eyes to reduce wrinkles or applied to the face for other benefits. There are also products like lip butters that can be applied to the lips for moisture and smoothness.

graduation

Whether you are looking for a topical agent for pain relief or recreational purposes, there are many choices. This wide variety of products is perfect for those who are new to cannabis and don’t want to smoke it, but still want to benefit from its effects.

All you have to do is apply such a product directly to the skin and wait a while. They are easier to control in their dosage and are not as potent as smoking marijuana. Make them more accessible to all types of users.

Continue Reading

CBD

Tauriga Sciences Inc. Generates Record Daily E-Commerce Revenue for Sunday, July 25, 2021

Published

on

1. PRESS RELEASE PICTURE for July 26th

TAURI soap product line (6 SKUs / 6 fragrances)

TAURI soap product line (6 SKUs / 6 fragrances)

The company generated more than $ 13,000.00 in e-commerce sales for the date: July 25, 2021

NEW YORK, NY, July 26, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a diversified life sciences company headquartered in New York, today announced that it has set a new one-day (“Daily”) e-commerce sales record for Sunday, July 25th, 2021. The company had more than $ 13,000 in e-commerce sales, or nearly 200 individual transactions, on July 25, 2021.

This “daily” e-commerce sales record was driven by the latest additions to product inventory, including: 1) TAURI soap and candle product lines (6 fragrances: pomegranate, blood orange, peach-lemon, pear bellini, mint and blackcurrant), 2) Delta 8 THC (25 mg) + Melatonin (5 mg) Infused Gummy Bears with Wild Blueberry Flavor, 3) CBD Isolate (25 mg) Infused Gummy Bears with Blue Raspberry / Strawberry Flavor, 4) TAURI Tropical Topical Body Butter Infused with CBD oil (120 mg.)), 5) TAURI coconut milk chocolate squares, enriched with full-spectrum CBD (“hemp”) extract (25 mg), 6) TAURI-Diabetic Friendly full-spectrum CBD (“hemp”) – Enriched Extract (25 mg) + Immunity Boost & Melatonin Lavender Chocolate Squares, 7) Tauri-Sun ™ 30 SPF CBD Isolate Infused (200 mg) Sunscreen Spray and 8) Tauri-Sun ™ 30 SPF CBD Infused Acai Fragrance Moisturizing Lip Balm .

Please visit the company’s e-commerce website:

WWW.TAURIGUM.COM

The company fully anticipates the arrival of inventory for its upgraded Tauri-Gum ™ product line (9 SKUs + 2 Limited Edition SKUs) later this week. Upon receipt, the company will fulfill its Tauri-Gum ™ pre-orders and meet with buyers from a wide range of potential retail customers. In addition, the company is confident that its e-commerce business will benefit significantly from the availability of its flagship brand, Tauri-Gum ™.

ABOUT TAURIGA SCIENCES INC.

The story goes on

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life science company that is involved in several key business activities and initiatives. The company manufactures and sells several proprietary retail products and product lines primarily focused on the cannabidiol (“CBD”) and cannabigerol (“CBG”) edibles market segments. The main Tauri-Gum ™ branded product line consists of a proprietary dietary supplement chewing gum that is Kosher Certified, Halal Certified and Vegan Formulated (CBD Infused Tauri-Gum ™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused.) Tauri-Gum ™ flavors: peach-lemon, blackcurrant), (Tauri-Gum ™ flavor enriched with vitamin C + zinc: Bellini pear), (Tauri-Gum ™ flavor enriched with caffeine: Cherry Lime Rickey) & (vitamin D3 enriched Tauri -Gum ™ Flavor: Golden Raspberry). The company’s commercialization strategy consists of a wide range of retail customers, distributors and a rapidly growing e-commerce business segment (e-commerce website: www.taurigum.com). Further information and inquiries can be found on our company website at http://www.tauriga.com

Complementary to the company’s retail business is its ongoing pharmaceutical development initiative. This relates to the development of a proposed pharmaceutical version of Tauri-Gum ™ for the control of nausea (specifically designed for the following indication: patients undergoing ongoing chemotherapy). On March 22, 2021, the company announced that it had converted its U.S. provisional patent application (filed March 17, 2020) into a U.S. non-provisional patent application. The patent filed with the USPTO is entitled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020, the company announced that it had entered into a master services agreement with CSTI to lead the company’s clinical development efforts.

The company is headquartered in Wappingers Falls, New York. The company also operates two full-time e-commerce fulfillment centers: one in Montgomery, Texas and the other in Brooklyn, New York.

DISCLAIMER – Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect management’s beliefs and beliefs about future events. These forward-looking statements are often identified by the use of words such as “may,” “will,” “expects,” “expects,” believes, “hopes,” “believes,” or plans and may include statements about company goals such as z and the achievement of certain company goals and milestones. Forward-looking statements are based on current circumstances and management’s current views with respect to events that did not occur, that may not occur, or that may have different consequences or timing than now believed or expected. Actual results could differ materially from known and unknown risks and uncertainties from those expressed in forward-looking statements upon successful acquisition and licensing transactions, currency fluctuations and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are further discussed in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings that may be filed with the Securities and Exchange Commission from time to time. Such forward-looking statements are made only as of this date and Tauriga assumes no obligation to update any forward-looking statements to reflect future events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.

4 Nancy Court, Suite 4

Wappingers Falls, NY 12590

Managing Director

Mr. Seth M. Shaw

Email: sshaw@tauriga.com

Cell # (917) 796 9926

Company Instagram: @taurigum

Personal Instagram: @ sethsms47

Twitter: @SethMShaw

Corp. Website: www.tauriga.com

E-commerce website: www.taurigum.com

Appendix

Continue Reading
Advertisement

Trending